EFB Dengue Literature Review

DN2 Gating Strategy

11 min read

DN2 Gating Strategy for Dengue EF B Cell Identification

Research Question

What is the optimal gating strategy to isolate DN (IgD⁻CD27⁻) B cells and DN2-phenotype (CD21⁻CD11c⁺) B cells from dengue patient whole-blood leukocytes (RBC-lysed whole blood, not Ficoll-separated PBMCs) using the curator’s fixed 11-color panel?

Sources Used

Panel

FluorochromeMarkerRole
PerCP-Cy5-5CD19B cell lineage
PE-Cy7CD66bDump (granulocytes)
PECD11cDN2 subgating
FITCCD21DN2 subgating
BV421CD38PB exclusion + transitional exclusion
AmCyanL/DViability
BV711CD3 + CD14Dump (T cells + monocytes)
BV785IgDDN gating
APCCD27PB exclusion + DN gating
AF700CD24Transitional exclusion
APC-H7CD45Leukocyte gate

Sanz2025 IgD audit: PASS. IgD (BV785) is included, distinguishing true IgD⁻CD27⁻ (DN) cells from activated memory B cells that may lose CD27 but retain IgD.

Synthesis

Canonical Gating Tree (Start → All Subpopulations)

At-a-glance map of the full B-cell immunophenotype the panel resolves. Per-step detail, FMO mandates, and double-count fixes follow in the subsections below — this block summarizes and links, it does not replace them.

Singlets → Live (L/D⁻) → Dump⁻ (CD3/CD14/CD66b⁻) → CD19⁺ B cells
│
├─ Plasmablasts ── CD27ʰⁱ CD38ʰⁱ            ← pulled out FIRST (Step 3)
│
└─ Non-PB B cells → IgD × CD27 quadrant (Step 5)
   ├─ Naïve ─────────────── IgD⁺ CD27⁻
   ├─ Unswitched memory ─── IgD⁺ CD27⁺ ─┐
   ├─ Switched memory (sM)─ IgD⁻ CD27⁺ ─┤→ split CD21: resting (CD21⁺) / activated (CD21⁻)
   └─ DN ────────────────── IgD⁻ CD27⁻
         └─ CD21 × CD11c (Step 6)
            ├─ DN1-like ──────────── CD21⁺ CD11c⁻
            ├─ (transitional-DN) ─── CD21⁺ CD11c⁺
            ├─ DN2-phenotype / ABC ─ CD21⁻ CD11c⁺   ★ EF target
            └─ DN3-like ──────────── CD21⁻ CD11c⁻

The CD21 resting (CD21⁺) / activated (CD21⁻) split applies across the whole CD27⁺ memory pool — both unswitched and switched — but is only switched-specific once gated IgD⁻ first (see reconciliation #1 below). Transitional B cells (CD24ʰⁱCD38ʰⁱ, Step 4) are excluded before the quadrant, not a terminal subset.

Terminal populations isolated (9): Plasmablasts · Naïve · Unswitched memory · Resting sM · Activated sM · DN1-like · transitional-DN (CD21⁺CD11c⁺) · DN2-phenotype/ABC · DN3-like.

Cuts: IgD/CD27/CD21/CD11c boundaries are FMO-anchored from the HT82 worked example — IgD<1.98, CD27<1.76, CD21<0.69, CD11c>0.72 (arcsinh/500), see Compensation and FMO Controls. The four definitional overlaps to avoid double-counting are resolved in § Reconciling the Expanded Gating Tree.

Gating Hierarchy

The strategy follows Ansari et al. 2025 (dengue) as the primary template, with Woodruff et al. 2020 (COVID-19) DN subgating as the reference standard.

STEP 0a ─ SINGLETS
  X-axis: FSC-A    Y-axis: FSC-H
  → Draw a diagonal gate along the FSC-A = FSC-H line
  → Exclude doublets (events that fall below the diagonal)
  
STEP 0b ─ MORPHOLOGICAL GATE
  X-axis: FSC-A    Y-axis: SSC-A
  → Generous gate including lymphoblast region
  ⚠ Do NOT draw a tight lymphocyte gate — activated B cell blasts
    (higher FSC/SSC) will be systematically excluded.
    Alternative: skip this gate and rely on lineage markers only.
  
STEP 1 ─ LIVE LEUKOCYTES
  X-axis: APC-H7 (CD45)    Y-axis: AmCyan (L/D)
  → Gate on CD45⁺ (right) and L/D⁻ (bottom) = live leukocytes
  
STEP 2a ─ DUMP GATE
  X-axis: BV711 (CD3 + CD14)    Y-axis: SSC-A
  → Gate on BV711⁻ (left) = exclude T cells and monocytes

STEP 2b ─ GRANULOCYTE EXCLUSION
  X-axis: PE-Cy7 (CD66b)    Y-axis: SSC-A
  → Gate on CD66b⁻ (left) = exclude granulocytes

STEP 2c ─ B CELL SELECTION
  X-axis: PerCP-Cy5-5 (CD19)    Y-axis: SSC-A
  → Gate on CD19⁺ (right) = B cells
  ⚠ CD3 and CD14 antibodies must be titrated independently before
    pooling in BV711 channel.
  
STEP 3 ─ EXCLUDE PLASMABLASTS / ASCs
  X-axis: APC (CD27)    Y-axis: BV421 (CD38)
  → Polygon gate around CD27ʰⁱCD38ʰⁱ cluster (upper-right)
  → Exclude this population
  ⚠ Use a polygon gate hugging the PB cluster, NOT a quadrant line.
    A quadrant risks losing CD27⁺CD38ᵐⁱᵈ activated memory B cells.
  
STEP 4 ─ EXCLUDE TRANSITIONAL B CELLS
  X-axis: AF700 (CD24)    Y-axis: BV421 (CD38)
  → Polygon gate around CD24ʰⁱCD38ʰⁱ cluster (upper-right)
  → Exclude this population
  ⚠ Set this gate on the POST-Step-3 population specifically.
    CD38 dynamic range is compressed after PB removal.
    Validate with CD10 in a separate tube if available.
  
STEP 5 ─ DN GATE (IgD vs CD27 quadrant)
  X-axis: BV785 (IgD)    Y-axis: APC (CD27)
Naive
IgD⁺ CD27⁻		Unswitched Memory
IgD⁺ CD27⁺
★ DN ★
IgD⁻ CD27⁻		Switched Memory
IgD⁻ CD27⁺
  → Gate on the IgD⁻CD27⁻ (lower-left) quadrant = DN B cells
  
STEP 6 ─ DN SUBGATING (CD21 vs CD11c)
  X-axis: FITC (CD21)    Y-axis: PE (CD11c)
  — within DN gate only
DN1-like
CD21⁺ CD11c⁻		CD21⁺ CD11c⁺
DN3-like
CD21⁻ CD11c⁻		★ DN2-phenotype ★
CD21⁻ CD11c⁺
  → DN2-phenotype = CD21⁻CD11c⁺
  → DN1-like = CD21⁺CD11c⁻
  → DN3-like = CD21⁻CD11c⁻
  
  ⚠ CRITICAL: CD11c-PE FMO control is MANDATORY on every acquisition.
    CD11c is dim on B cells. PE-Cy7 (CD66b) tandem dye degradation
    creates spillover into PE that can produce false CD11c positivity.
  ⚠ CD21 FITC FMO also required — FITC is a relatively dim
    fluorochrome and FITC→PE spread must be compensated.

Isolating Switched Memory (sM) and the Resting/Activated Memory Split

Switched memory (sM = IgD⁻CD27⁺) is the Step-5 lower-right quadrant — previously read only as a reference population, now isolated as the germinal-center comparator to the DN/DN2 extrafollicular cells (see Switched Memory B Cell). It sits directly beside DN (IgD⁻CD27⁻): both are class-switched, differing only by CD27. Within sM, subdivide on CD21:

Resting switched memory
CD21⁺ CD38⁻		Activated switched memory
CD21⁻ (continuum toward atypical/DN2)

This makes the sM and DN gates a matched GC-vs-EF pair: comparing them (SHM, repertoire, isotype, autoreactivity, kinetics) is the readout that tests whether DN is a distinct EF lineage or CD27-shed switched memory.

Reconciling the Expanded Gating Tree (4 Overlaps)

When the panel is run as a full B-cell immunophenotype (plasmablasts + CD27⁺ memory subsets + naïve + sM + DN subgates) rather than DN-only, four definitional overlaps must be resolved to avoid double-counting:

  1. Memory gates must be IgD-anchored. A CD27⁺CD38⁻CD24⁺ memory gate split only by CD21 mixes switched (IgD⁻) and unswitched (IgD⁺) memory. For a clean switched-memory resting/activated split, gate IgD⁻ first (= sM), then split by CD21 — otherwise “resting/activated memory” is not switched-specific and overlaps the sM quadrant.
  2. “ABCs” ≡ “DN CD21⁻CD11c⁺” ≡ DN2-phenotype — these are the same gate (the CD21⁻CD11c⁺ quadrant within IgD⁻CD27⁻ DN). Use a single label (“DN2-phenotype,” per Ansari2025/Sanz2025 convention) so the population is not listed twice.
  3. The DN 2×2 needs all four quadrants. DN1-like (CD21⁺CD11c⁻), CD21⁺CD11c⁺ (unnamed transitional-DN), DN2-phenotype (CD21⁻CD11c⁺), and DN3-like (CD21⁻CD11c⁻). Omitting CD21⁻CD11c⁻ means the DN subsets will not sum to 100% of DN.
  4. CD24 serves two roles — keep the levels distinct. CD24 is used for transitional exclusion (CD24ʰⁱCD38ʰⁱ, Step 4); if it is also used for memory inclusion (CD24-intermediate), that level must be clearly separated from the CD24ʰⁱ transitional gate, or the channel double-counts.

Backgating Verification

After gating, verify all subsets by backgating onto parent populations:

  • Backgate DN2-phenotype cells onto FSC/SSC to confirm they fall within the morphological gate
  • Backgate onto CD19 vs SSC to confirm clean B cell identity
  • Backgate onto IgD vs CD27 to confirm they remain in the IgD⁻CD27⁻ quadrant

Comparison to Published Strategies

FeatureThis panelAnsari2025 (dengue)Woodruff2020 (COVID-19)Wei2007 (SLE)
Colors1115+24 (spectral)8
CD19⁺ lineageYesYesYesYes
Dump channelCD3/CD14/CD66b/L/DCD14/CD16/CD3/DeadComprehensiveCD3
PB exclusionCD27ʰⁱCD38ʰⁱCD38⁻CD27⁻ pre-enrichmentCD27 vs CD38—
Transitional exclusionCD24ʰⁱCD38ʰⁱCD24⁻CD38⁻CD24 vs CD38—
DN gateIgD⁻CD27⁻IgD⁻CD27⁻IgD⁻(IgM⁻)IgD⁻CD27⁻
DN2 resolutionCD21⁻CD11c⁺CD21⁻CD11c⁺CD21⁻CD11c⁺ + CXCR5⁻—
CXCR5NoNoYesNo
T-betNoNoYes (intracellular)No
IgM/IgGNoLikely yesYesYes
IgD includedYesYesYesYes
Sanz2025 IgD auditPASSPASSPASSPASS

Key comparability note: DN2-phenotype frequencies (% of CD19⁺ B cells) are directly comparable between this panel and Ansari2025. The gating order differs slightly (this panel excludes PBs and transitionals as separate steps; Ansari pre-enriches with CD38⁻CD27⁻ before IgD/CD27 quadrant), but the final DN and DN2 populations are defined identically.

Terminology: “DN2-phenotype” Not “DN2”

The formal Jenks2018 DN2 definition requires: IgD⁻, CD27⁻, CXCR5⁻, CD21⁻, CD11c⁺, CD19ʰⁱ, T-bet⁺, FCRL5⁺. This panel lacks CXCR5, T-bet, and FCRL5. The population isolated at Step 6 is therefore “DN2-phenotype” — enriched for but not formally confirmed DN2.

This is the same limitation Ansari et al. 2025 had. In SLE, Jenks2018 showed >90% concordance between CD21⁻CD11c⁺ and T-bet⁺ within the DN gate, and CD21⁻ is a strong surrogate for CXCR5⁻ (discordant fraction <5–10%). Whether this concordance holds in dengue is unknown.

All reporting should use “DN2-phenotype” throughout, following Ansari2025 precedent.

Council-Identified Risks and Mitigations

MAJOR: PE-Cy7 → PE Spectral Spread (Methodology Critic)

CD11c on PE is the gate-defining marker for DN2-phenotype. CD66b on PE-Cy7 can bleed into PE via tandem dye degradation. Since CD11c is dim on B cells, even modest spillover produces false positivity.

Mitigation: CD11c-PE FMO control on every acquisition. Empirically assess PE-Cy7→PE spread. Consider running a compensation validation with CD66b-PE-Cy7 single-stain at high concentration.

MAJOR: CD27 Shedding Contamination (Claims Validator)

Dengue is a high-TNF/IL-6 environment. ADAM17-mediated CD27 cleavage on activated switched memory B cells could place them in the IgD⁻CD27⁻ gate. If also CD11c⁺ upon activation, they contaminate the DN2-phenotype gate.

Mitigation: Not solvable within this panel. Must acknowledge as a limitation in all reporting. Measuring soluble CD27 in matched serum samples could quantify the extent of shedding. If sCD27 is elevated, DN frequencies should be interpreted with caution.

MAJOR: Post-PB-Exclusion CD38 Compression (Methodology Critic)

After removing CD38ʰⁱ plasmablasts (Step 3), the remaining CD38 dynamic range is compressed, making the CD24ʰⁱCD38ʰⁱ transitional gate harder to resolve.

Mitigation: Always set the Step 4 gate on the post-Step-3 population. If a separate validation tube with CD10 is available, use CD10⁺ to validate the transitional gate boundary. In adult dengue whole blood, transitional B cells are typically rare, so modest imprecision has limited quantitative impact.

MAJOR: FSC/SSC Blast Exclusion (Methodology Critic)

Tight lymphocyte morphological gates exclude activated B cell blasts (larger, more granular).

Mitigation: Draw the FSC/SSC gate generously to include the lymphoblast region. Alternatively, omit the morphological gate and rely on CD45/lineage markers for cleanup. Either approach is acceptable; the generous gate is preferred for consistency with published protocols.

What This Panel Resolves

  • Total DN (IgD⁻CD27⁻) frequency and kinetics in dengue
  • DN2-phenotype (CD21⁻CD11c⁺) frequency — directly comparable to Ansari2025
  • DN1-like (CD21⁺CD11c⁻) and DN3-like (CD21⁻CD11c⁻) frequencies
  • All four IgD/CD27 B cell quadrants (naive, unswitched memory, switched memory, DN)
  • Resting (CD21⁺) vs activated (CD21⁻) switched memory split within the sM (IgD⁻CD27⁺) quadrant
  • Plasmablast (CD27ʰⁱCD38ʰⁱ) frequency
  • Transitional B cell (CD24ʰⁱCD38ʰⁱ) frequency
  • Cross-disease DN2-phenotype benchmarking vs. SLE (Jenks2018) and COVID-19 (Woodruff2020)

What This Panel Cannot Resolve

GapMissing markerImpact
Formal DN2 confirmationCXCR5, T-bet, FCRL5Must use “DN2-phenotype” terminology
DN1 vs DN3 distinctionCXCR5Both are CD21⁺ or CD21⁻ but CXCR5⁺ vs CXCR5⁻
Isotype within DN2IgM, IgG, IgACannot determine class-switch status
Proliferative statusKi-67Cannot assess active cycling
CD27 shedding vs true DNsCD27 or secondary markerCannot distinguish loss from absence
DENV antigen specificityTetramer / antigen probesCannot determine DENV-binding fraction
Long-lived PC phenotypeCD138Cannot assess ASC maturation state

Panel Strengths (Council Assessment)

  1. Direct Ansari2025 comparability — the only dengue DN2 reference. Generates the second-ever dengue DN2-phenotype dataset (STRONG).
  2. 11-color efficiency — achieves DN subgating with cleanup on conventional instruments. Accessible to dengue-endemic-setting labs without spectral capability (STRONG).
  3. Sanz2025 IgD audit compliant — credible DN reporting; multiple dengue studies fail this criterion (STRONG).
  4. Comprehensive dump — CD3, CD14, CD66b, L/D removes T cells, monocytes, granulocytes, and dead cells. CD66b inclusion is an improvement over Ansari2025 (MODERATE).
  5. CD24 transitional exclusion — absent from most dengue B cell panels (MODERATE).

Open Questions

  • Does the CD21⁻/CXCR5⁻ concordance established in SLE (Jenks2018, <5–10% discordance) hold in acute dengue? This determines whether “DN2-phenotype” approximates true DN2.
  • How much CD27 shedding occurs in acute dengue? Elevated sCD27 would inflate apparent DN frequencies. No dengue study in the wiki quantifies this.
  • Can a second-tube validation panel (adding CXCR5, T-bet intracellular, IgM, IgG) be run on a subset of samples to calibrate the primary panel’s DN2 purity?
  • Is the DN2-phenotype:DN1-like ratio informative of disease severity in dengue, as it is in SLE (Jenks2018) and COVID-19 (Woodruff2020)?
  • Does the DN2-phenotype expansion track with days post-fever-onset, paralleling or preceding the plasmablast wave?

B Cell Panel Variant 1 (intracellular-capable successor — adds T-bet/CXCR5), Double-Negative B Cell, DN2 B Cell, DN3 B Cell, Switched Memory B Cell, Plasmablast, CD21, CD11c, CD27, IgD, CD38, CD24, CXCR5, T-bet, FCRL5, Extrafollicular Response, Conventional Flow Cytometry, Spectral Flow Cytometry, FACS Sorting, Compensation and FMO Controls, DN2 Panel - Staining, Compensation, and Gating Protocol, Research Plan - DN B Cell Expansion in Dengue

Graph View

Backlinks